Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Shares Outstanding (Weighted Average): 2015-2024

Historic Shares Outstanding (Weighted Average) for Editas Medicine (EDIT) over the last 10 years, with Dec 2024 value amounting to $82.5 million.

  • Editas Medicine's Shares Outstanding (Weighted Average) rose 9.03% to $89.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.9 million, marking a year-over-year increase of 9.03%. This contributed to the annual value of $82.5 million for FY2024, which is 1.07% up from last year.
  • According to the latest figures from FY2024, Editas Medicine's Shares Outstanding (Weighted Average) is $82.5 million, which was up 1.07% from $81.7 million recorded in FY2023.
  • Editas Medicine's Shares Outstanding (Weighted Average)'s 5-year high stood at $82.5 million during FY2024, with a 5-year trough of $62.3 million in FY2020.
  • In the last 3 years, Editas Medicine's Shares Outstanding (Weighted Average) had a median value of $81.7 million in 2023 and averaged $77.7 million.
  • Data for Editas Medicine's Shares Outstanding (Weighted Average) shows a peak YoY climbed of 21.50% (in 2020) over the last 5 years.
  • Over the past 5 years, Editas Medicine's Shares Outstanding (Weighted Average) (Yearly) stood at $62.3 million in 2020, then increased by 9.73% to $68.4 million in 2021, then rose by 0.53% to $68.8 million in 2022, then grew by 18.78% to $81.7 million in 2023, then grew by 1.07% to $82.5 million in 2024.